Prohance

Prohance is a brand name of gadoteridol, approved by the FDA in the following formulation(s):

PROHANCE (gadoteridol - injectable; injection)

• 
  Manufacturer: BRACCO
  
  Approval date: November 16, 1992
  
  Strength(s): 279.3MG/ML ^[RLD]

Has a generic version of Prohance been approved?

No. There is currently no therapeutically equivalent version of Prohance available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Prohance. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Method for imaging mammalian tissue using 1-substituted-1,4,7-tricarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs
  Patent 5,474,756
  Issued: December 12, 1995
  Inventor(s): Tweedle; Michael F. & Gaughan; Glen T. & Hagan; James J.
  Assignee(s): Bracco International B.V.
  A method for imaging mammalian tissue utilizing a non-ionic complex of a paramagnetic ion of lanthanide element and a macrocyclic chelating agent.
  
  Patent expiration dates:
  
  
  • December 12, 2012
    
    ✓ 
    Patent use: CONTRAST AGENT FOR MRI
  
  



• 
  Method for imaging mammalian tissue using 1-substituted-1,4,7-tricarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs
  Patent 5,846,519
  Issued: December 8, 1998
  Inventor(s): Tweedle; Michael F. & Gaughan; Glen T. & Hagan; James J.
  Assignee(s): Bracco Diagnostics Inc.
  A method for imaging mammalian tissue utilizing a non-ionic complex of a paramagnetic ion of lanthanide element and a macrocyclic chelating agent.
  
  Patent expiration dates:
  
  
  • December 8, 2015
    
  
  



• 
  Method for imaging and radiopharmaceutical therapy using 1-substituted-4,7,10-tricarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs
  Patent 6,143,274
  Issued: November 7, 2000
  Inventor(s): Tweedle; Michael F. & Gaughan; Glen T. & Hagan; James J.
  A method for imaging mammalian tissue utilizing a non-ionic complex of a paramagnetic ion of lanthanide element and a macrocyclic chelating agent.
  
  Patent expiration dates:
  
  
  • December 12, 2012
    
    ✓ 
    Patent use: CONTRAST AGENT FOR MRI
  
  

See also...

• Prohance Advanced Consumer Information (Micromedex)
• Gadoteridol Intravenous Advanced Consumer Information (Micromedex)